On Thursday, Shares of Yamana Gold, Inc. (NYSE:AUY), dropped -4.50% to $3.82.
Yamana Gold, declared a second quarter 2015 dividend of $0.015 per share. Shareholders of record at the close of business on June 30, 2015 will be entitled to receive payment of this dividend on July 14, 2015. The dividend is an “eligible dividend” for Canadian tax purposes.
The Company provides shareholders with the option to take part in a Dividend Reinvestment Plan (“DRIP”). Participants in the DRIP may obtain additional common shares of the Company by automatically reinvesting all or any portion of the cash dividends paid on common shares held by the DRIP participant without paying any brokerage commissions, administrative costs or other service charges. The enrollment forms are accessible on the Company’s website at www.yamana.com and under Yamana’s profile on CST’s website at www.canstockta.com. All shareholders considering enrollment in the DRIP should carefully review the terms of the DRIP and consult with their advisors as to the implications of enrollment in the DRIP.
Yamana Gold Inc. engages in gold mining and related activities, counting exploration, extraction, processing, and reclamation. The company has precious metal properties and land positions in the Americas.
Shares of MBIA Inc. (NYSE:MBI), declined -4.48% to $8.75, during its last trading session.
MBIA, will host a webcast and conference call for investors on Tuesday, May 12 at 8:00 a.m. (EDT) to talk about its first quarter 2015 financial results and other issues related to the Company. The dial-in number for the call is (877) 694-4769 in the U.S. and (404) 665-9935 from outside the U.S. The conference call code is 31617213.
The conference call will comprise of brief comments on the first quarter 2015 results followed by a question and answer session for investors. MBIA’s financial results press release and 10-Q filing will be issued after the market closes on Monday, May 11, 2015.
MBIA Inc. provides financial guarantee insurance services to public finance markets in the United States and internationally. The company operates through U.S. Public Finance Insurance, and International and Structured Finance Insurance segments.
At the end of Thursday’s trade, Shares of Incyte Corporation (NASDAQ:INCY), dwindled -4.44% to $97.16.
Incyte Corporation, stated 2015 first-quarter financial results, counting revenue from Jakafi® (ruxolitinib). In addition to the strong performance of Jakafi in the quarter, the Company highlighted the successful result of the second baricitinib Phase III trial in rheumatoid arthritis, as declared with Lilly, and the publication, in the New England Journal of Medicine, of the Phase III RESPONSE trial results of Jakafi in patients with uncontrolled polycythemia vera (PV). During the first quarter Incyte expanded its discovery capabilities with an immuno-therapeutic alliance with Agenus Inc. (Agenus), and has recently further highlighted its emerging pipeline with the publication of eleven abstracts at the annual meeting of the American Association for Cancer Research (AACR).
In April 2015, Incyte declared its intention to establish the new headquarters of Incyte Europe Sarl (Incyte Europe) in Geneva, Switzerland. The Company intends to use Incyte Europe as the base from which to conduct its European clinical development operations.
Jakafi® is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis and for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), counting primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF.
Finally, CEMEX, S.A.B. de C.V. (NYSE:CX), ended its last trade with -4.37% loss, and closed at $9.62.
CEMEX, declared that as a result of the application of retained earnings for a capital enhance approved by CEMEX’s shareholders at the general ordinary shareholders meeting held on March 26, 2015, CEMEX shareholders will receive new shares as follows:
- 1 new CEMEX CPO per 25 CEMEX CPOs held, or, if applicable, 3 new shares per 75 shares presently outstanding.
- Holders of CEMEX American Depositary Shares (“ADS”) will receive 1 newly issued ADS per 25 ADSs held.
- No cash will be distributed by CEMEX, counting for fractions for which no shares are issued.
CEMEX, S.A.B. de C.V., a building materials company, produces, markets, distributes, and sells cement, ready-mix concrete, aggregates, and other construction materials in Mexico, the United States, Northern Europe, the Mediterranean, South America, the Caribbean, and Asia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
